Skip to content
MarketScale
‹ Back to IndustriesHealthcare

A Pulmonary Expert Weighs in on the Johnson & Johnson COVID-19 Vaccine’s Pause

The mission of Health Matters is to promote health equity by elevating the conversation around healthy habits, preventative health, and relevant public health issues. By approaching these topics with an equitable lens, we can all do our part to empower individuals to make more informed decisions about their health and care.   On this episode,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

The mission of Health Matters is to promote health equity by elevating the conversation around healthy habits, preventative health, and relevant public health issues. By approaching these topics with an equitable lens, we can all do our part to empower individuals to make more informed decisions about their health and care.

On this episode, hosts Dr. Jose Medina-Inojosa and Alisa Johnsrud talked with Jonathan Baktari, MD, about the Johnson and Johnson vaccine pause due to potentially fatal blood clots after one American died and one is in critical condition. Baktari is a pulmonary and critical care expert, vaccine expert, CEO of two medical companies —e7Health.com and US Drug Test Centers.

“It’s interesting. The mRNA vaccine has been around for ten years” -Jonathan Baktari, MD

The trio talked about the Johnson and Johnson vaccine and the importance of the other vaccines. Baktari said the vaccine would be part of the solution to get to herd immunity, so even though it’s currently delayed, it will be an essential piece of the puzzle. The Moderna and Pfizer vaccine use mRNA to introduce the virus, while the J&J vaccine uses the adenovirus.

“It’s interesting. The mRNA vaccine has been around for ten years,” Baktari said. He elaborated that nobody had the guts to use mRNA because folks would have been hesitant to inject genetic material. The pandemic, however, forced us to use the technology.

Vaccines have always been a sensitive subject, as some don’t want to use vaccines. For Baktari, he doesn’t understand the hesitancy. He noted that people are still so willing to use antibiotics and other drugs, but they don’t like it when it comes to vaccines. One of the reasons he thinks is because the government advises it.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Healthcare AI deployments stall on data quality, not model performance

Healthcare AI deployments stall on data quality, not model performance

Healthcare AI deployments are facing challenges not with the AI models themselves, but with the data quality. Hospital CIOs report difficulties in scaling AI due to fragmented and poorly governed data. This highlights the need for better data management and governance in healthcare AI initiatives.

  • 01Data quality is a major obstacle in scaling healthcare AI deployments.
  • 02Hospital CIOs are encountering issues with fragmented data governance.
  • 03AI model performance is not the primary challenge in these initiatives.

Jul 11, 2026

NHS commits £10bn to health tech, with ambient voice and pathology digitization at the center

NHS commits £10bn to health tech, with ambient voice and pathology digitization at the center

NHS England is investing £10bn in health technology, focusing on ambient voice technology and pathology digitization. This initiative aims to improve healthcare efficiency and patient outcomes. The commitment includes integrating advanced technologies into existing healthcare systems.

  • 01NHS England commits £10bn to health tech.
  • 02Focus areas include ambient voice technology and pathology digitization.
  • 03The initiative aims to enhance healthcare efficiency and patient care.

Jul 9, 2026

Canada launches Vital, a national hospital data platform backed by $210 million, starting with 160 hospitals

Canada launches Vital, a national hospital data platform backed by $210 million, starting with 160 hospitals

Canada has introduced a national hospital data platform named Vital, which will initially connect real-time data from 160 hospitals across three provinces. The initiative is supported by $210 million in funding, with coordination provided by Unity Health Toronto. This platform aims to enhance healthcare data integration and accessibility across the country.

  • 01Vital platform will connect 160 hospitals across three Canadian provinces.
  • 02The initiative is supported by $210 million in funding.
  • 03Unity Health Toronto is coordinating the implementation of this platform.

Jul 8, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub